TY - JOUR
T1 - The novel prostate cancer antigen 3 (PCA3) biomarker
AU - Bourdoumis, Andreas
AU - Papatsoris, Athanasios G.
AU - Chrisofos, Michael
AU - Efstathiou, Eleni
AU - Skolarikos, Andreas
AU - Deliveliotis, Charalambos
PY - 2010/12
Y1 - 2010/12
N2 - PCA3 is a prostate specific, nonprotein coding RNA that is significantly over expressed in prostate cancer, without any correlation to prostatic volume and/or other prostatic diseases (e.g. prostatitis). It can now easily be measured in urine with a novel transcription-mediated amplification based test. Quantification of PCA3 mRNA levels can predict the outcome of prostatic biopsies with a higher specificity rate in comparison to PSA. Several studies have demonstrated that PCA3 can be used as a prognostic marker of prostate cancer, especially in conjunction with other predictive markers. Novel PCA3-based nomograms have already been introduced into clinical practice. PCA3 test may be of valuable help in several PSA quandary situations such as negative prostatic biopsies, concomitant prostatic diseases, and active surveillance. Results from relevant clinical studies, comparative with PSA, are warranted in order to confirm the perspective of PCA3 to substitute PSA.
AB - PCA3 is a prostate specific, nonprotein coding RNA that is significantly over expressed in prostate cancer, without any correlation to prostatic volume and/or other prostatic diseases (e.g. prostatitis). It can now easily be measured in urine with a novel transcription-mediated amplification based test. Quantification of PCA3 mRNA levels can predict the outcome of prostatic biopsies with a higher specificity rate in comparison to PSA. Several studies have demonstrated that PCA3 can be used as a prognostic marker of prostate cancer, especially in conjunction with other predictive markers. Novel PCA3-based nomograms have already been introduced into clinical practice. PCA3 test may be of valuable help in several PSA quandary situations such as negative prostatic biopsies, concomitant prostatic diseases, and active surveillance. Results from relevant clinical studies, comparative with PSA, are warranted in order to confirm the perspective of PCA3 to substitute PSA.
KW - Biopsy
KW - PCA3
KW - PSA
KW - Prostatic neoplasms
KW - Tumor marker
UR - http://www.scopus.com/inward/record.url?scp=79251503932&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79251503932&partnerID=8YFLogxK
U2 - 10.1590/S1677-55382010000600003
DO - 10.1590/S1677-55382010000600003
M3 - Review article
C2 - 21176272
AN - SCOPUS:79251503932
SN - 1677-5538
VL - 36
SP - 665
EP - 669
JO - International Braz J Urol
JF - International Braz J Urol
IS - 6
ER -